Stifel Nicolaus Raises Cipher Pharmaceuticals (TSE:CPH) Price Target to C$19.00

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its target price boosted by Stifel Nicolaus from C$17.00 to C$19.00 in a research report report published on Thursday morning, BayStreet.CA reports.

Other research analysts have also recently issued research reports about the company. Leede Financial cut Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th. Stifel Canada upgraded Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

Cipher Pharmaceuticals Stock Up 2.3 %

Shares of CPH opened at C$16.52 on Thursday. The company has a quick ratio of 2.67, a current ratio of 11.18 and a debt-to-equity ratio of 0.33. The business has a fifty day moving average of C$16.45 and a 200 day moving average of C$11.82. The company has a market cap of C$422.75 million, a PE ratio of 13.32 and a beta of 1.20. Cipher Pharmaceuticals has a 52-week low of C$4.30 and a 52-week high of C$19.69.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its earnings results on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.15 by C$0.01. The firm had revenue of C$7.26 million during the quarter, compared to analyst estimates of C$7.52 million. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. On average, sell-side analysts expect that Cipher Pharmaceuticals will post 1.6472868 EPS for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.